Japan government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's, newspaper says
19/02/2026 09:41
TOKYO, Feb 19 (Reuters) - A Japanese health ministry panel on Thursday endorsed Sumitomo Pharma's 4506.T iPS Cell-derived treatment for Parkinson's disease, the Mainichi Shimbun newspaper said. The panel also gave its endorsement to Cuorips's 4894.T iPS Cell-derived cardiomyocyte patches for the treatment of severe heart failure, the paper said. (Reporting by Kiyoshi Takenaka; Editing by Emelia Sithole-Matarise) ((kiyoshi.takenaka@thomsonreuters.com;))
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)